<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">LUP</journal-id>
<journal-id journal-id-type="hwp">splup</journal-id>
<journal-id journal-id-type="nlm-ta">Lupus</journal-id>
<journal-title>Lupus</journal-title>
<issn pub-type="ppub">0961-2033</issn>
<issn pub-type="epub">1477-0962</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0961203311425518</article-id>
<article-id pub-id-type="publisher-id">10.1177_0961203311425518</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Papers</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Evaluation of cardiac autonomic functions in patients with systemic lupus erythematosus</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Yorgun</surname><given-names>H</given-names></name>
<xref ref-type="aff" rid="aff1-0961203311425518">1</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Canpolat</surname><given-names>U</given-names></name>
<xref ref-type="aff" rid="aff1-0961203311425518">2</xref>
<xref ref-type="corresp" rid="corresp1-0961203311425518"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Aytemir</surname><given-names>K</given-names></name>
<xref ref-type="aff" rid="aff1-0961203311425518">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Ateş</surname><given-names>AH</given-names></name>
<xref ref-type="aff" rid="aff1-0961203311425518">3</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Kaya</surname><given-names>EB</given-names></name>
<xref ref-type="aff" rid="aff1-0961203311425518">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Akdoğan</surname><given-names>A</given-names></name>
<xref ref-type="aff" rid="aff1-0961203311425518">4</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Sunman</surname><given-names>H</given-names></name>
<xref ref-type="aff" rid="aff1-0961203311425518">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Canpolat</surname><given-names>A Gökçay</given-names></name>
<xref ref-type="aff" rid="aff1-0961203311425518">4</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Çalgüneri</surname><given-names>M</given-names></name>
<xref ref-type="aff" rid="aff1-0961203311425518">4</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Kabakçı</surname><given-names>G</given-names></name>
<xref ref-type="aff" rid="aff1-0961203311425518">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Tokgözoğlu</surname><given-names>L</given-names></name>
<xref ref-type="aff" rid="aff1-0961203311425518">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Oto</surname><given-names>A</given-names></name>
<xref ref-type="aff" rid="aff1-0961203311425518">2</xref>
</contrib>
</contrib-group>
<aff id="aff1-0961203311425518"><sup>1</sup>Polatlı Duatepe State Hospital, Ankara, Turkey; <sup>2</sup>Department of Cardiology, Hacettepe University, Ankara, Turkey; <sup>3</sup>Sinop Atatürk State Hospital, Sinop, Turkey; and <sup>4</sup>Department of Rheumatology, Hacettepe University, Ankara, Turkey</aff>
<author-notes>
<corresp id="corresp1-0961203311425518">Uğur Canpolat, M.D., Hacettepe University Faculty of Medicine, Department of Cardiology, Altındağ 06100, Ankara, Turkey Email: <email>dru_canpolat@yahoo.com</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>4</month>
<year>2012</year>
</pub-date>
<volume>21</volume>
<issue>4</issue>
<fpage>373</fpage>
<lpage>379</lpage>
<history>
<date date-type="received"><day>2</day><month>2</month><year>2011</year></date>
<date date-type="accepted"><day>9</day><month>9</month><year>2011</year></date>
</history>
<permissions>
<copyright-statement>© The Author(s), 2011. Reprints and permissions: http://www.sagepub.co.uk/journalsPermissions.nav</copyright-statement>
<copyright-year>2011</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p><italic>Background:</italic> Cardiovascular involvement is one of the leading causes of death among patients with systemic lupus erythematosus (SLE). In this study, we aimed to investigate cardiac autonomic functions in SLE patients. <italic>Methods:</italic> We enrolled 36 patients (25 female; mean age 34.2 ± 10.2 years) with SLE and 32 healthy subjects (23 female; mean age 35.0 ± 10.3 years). All participants underwent 24-h Holter recording. Heart rate recovery (HRR) indices were calculated by subtracting first, second, and third-minute heart rates from maximal heart rate. All patients underwent heart rate variability (HRV), heart rate turbulence (HRT) and QT dispersion analysis. The mean SLE duration was 8.4 ± 4.0 years. <italic>Results:</italic> According to the baseline demographic characteristics, both groups were similar with regard to age, gender, body mass index and left ventricular ejection fraction. Mean HRR1 (32.6 ± 10.9 vs. 42.5 ± 6.5, <italic>p</italic> = 0.038), HRR2 (51.0 ± 16.9 vs. 61.0 ± 10.8, <italic>p</italic> = 0.01) and HRR3 (52.8 ± 17.5 vs. 65.8 ± 9.8, <italic>p</italic> &lt; 0.001) values were significantly higher in control group. When HRV was considered, SDNN, SDANN, RMSSD, PNN50 and high frequency (HF) component were significantly decreased in patients with SLE compared with healthy controls, but low frequency (LF) component and LF/HF were significantly higher in SLE patients. In addition, HRT onset and HRT slope values were significantly less negative in SLE patients. QT dispersion was significantly greater in SLE patients than healthy subjects (81.3 ± 15.8 vs. 53.2 ± 13.1, <italic>p</italic> &lt; 0.001). <italic>Conclusion:</italic> Our study results suggest that cardiac autonomic functions are impaired in SLE patients despite the absence of overt cardiac involvement and symptoms. Further studies are needed to elucidate the prognostic significance and clinical implications of impaired autonomic functions in patients with SLE.</p>
</abstract>
<kwd-group>
<kwd>heart rate recovery</kwd>
<kwd>heart rate variability</kwd>
<kwd>heart rate turbulence</kwd>
<kwd>QT dispersion</kwd>
<kwd>systemic lupus erythematosus</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="sec1-0961203311425518" sec-type="intro"><title>Introduction</title>
<p>Currently, cardiac involvement is one of the major concerns in the management of patients with autoimmune diseases. The cardiovascular system is an important target for systemic lupus erythematosus (SLE) involving the pericardium myocardium, endocardium, heart valves, and coronary vessels as well as cardiac autonomic functions.<sup><xref ref-type="bibr" rid="bibr1-0961203311425518">1</xref></sup> Thrombotic and atherosclerotic diseases are the most common causes of cardiovascular mortality in patients with SLE.<sup><xref ref-type="bibr" rid="bibr2-0961203311425518">2</xref>,<xref ref-type="bibr" rid="bibr3-0961203311425518">3</xref></sup> Although sinus tachycardia, atrial fibrillation and atrial ectopic beats are the major cardiac arrhythmias seen in SLE, cardiac conduction abnormalities can also be seen due to maternal SLE history or myocardial involvement.<sup><xref ref-type="bibr" rid="bibr4-0961203311425518">4</xref></sup> In addition, there have been reports of malignant ventricular dysrhythmias in SLE.<sup><xref ref-type="bibr" rid="bibr5-0961203311425518">5</xref></sup></p>
<p>The autonomic nervous system (ANS) is composed of the sympathetic and parasympathetic nervous system which control multiple organs, including the cardiovascular system. The cardiac ANS plays an integral role in the modulation of normal cardiac electrophysiology and regulating cardiac activity. In daily practice cardiac autonomic functions can be evaluated by several non-invasive methods based on the cardiac responses to physiological or pharmacological tests.</p>
<p>Abnormalities in the autonomic tone are potentially associated with worse prognosis, including life-threatening ventricular dysrhythmias and sudden cardiac death.<sup><xref ref-type="bibr" rid="bibr4-0961203311425518">4</xref></sup> Several previous studies have investigated the potential role of the ANS in autoimmune disorders, including SLE.<sup><xref ref-type="bibr" rid="bibr6-0961203311425518">6</xref>,<xref ref-type="bibr" rid="bibr7-0961203311425518">7</xref></sup> However, as yet there are few data regarding the involvement of ANS in SLE. In this study, we aimed to investigate several parameters of cardiac autonomic functions in patients with SLE compared with healthy control subjects.</p></sec>
<sec id="sec2-0961203311425518" sec-type="methods"><title>Methods</title>
<sec id="sec3-0961203311425518"><title>Study population</title>
<p>In this study we enrolled consecutively eligible outpatients of a rheumatology clinic with clinical evidence of SLE who met ≥4 American College of Rheumatology (ACR) revised criteria of SLE classification.<sup><xref ref-type="bibr" rid="bibr8-0961203311425518">8</xref></sup> Patients were excluded from the study if they (a) had acute or chronic infection; (b) were pregnant; (c) had diseases interfering with the ANS, including diabetes mellitus, renal and liver diseases, Parkinson’s disease and amyloidosis; (d) had cardiovascular diseases including hypertension, ischaemic heart disease, congestive heart failure, valvular heart disease, cardiomyopathy and cardiac arrhythmia; or (e) had neurological diseases including multiple sclerosis, polyneuropathy. Also, patients with known conventional cardiovascular risk factors including smoking, hypertension, dyslipidemia and diabetes mellitus were excluded from the analysis. Patients taking drugs that interfered with the ANS, including antihypertensive, adrenergic inhibitor, vasodilator, antiarrhythmic, sedative, hypnotic and antiepileptic drugs, were also excluded from the study. The study population consisted of 36 patients with SLE and 32 gender-, body mass index (BMI)-, and age-matched healthy subjects.</p>
<p>In all subjects, a detailed cardiovascular and systemic examination was performed at the beginning of the study with demographic data and anthropometric measures including weight, height, and BMI. 12-lead electrocardiography (ECG) at 25 mm/sec (paper speed), 24-h ambulatory ECG (AECG) monitoring, treadmill exercise testing, and transthoracic echocardiography by a System FiVe (GEVingmed<sup>®</sup> Ultrasound; Horten, Norway) cardiac ultrasonographic scanner, with 2.5–3.5 MHz transducers were performed in each participant. SLE activity was measured by Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) and damage by Systemic Lupus International Collaborating Clinics/ACR Damage Index (SLICC-DI).<sup><xref ref-type="bibr" rid="bibr9-0961203311425518">9</xref></sup><sup>–</sup><sup><xref ref-type="bibr" rid="bibr11-0961203311425518">11</xref></sup></p>
<p>Biochemical measurements for fasting blood glucose, total cholesterol, low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, triglyceride, C-reactive protein (CRP) levels, erythrocyte sedimentation rate (ESR), serum creatinine, and autoantibodies including anti-double stranded DNA (dsDNA) and anti-Smith (Sm) antibodies, were obtained from all patients with SLE. Treatment with azathioprine, methotrexate, and cyclophosphamide was recorded as immunosuppressive therapy.</p>
<p>Informed consent was taken from each patient and the study was approved by local ethics committee.</p></sec>
<sec id="sec4-0961203311425518"><title>Assessment of ANS</title>
<sec id="sec5-0961203311425518"><title>Heart rate recovery</title>
<p>To calculate heart rate recovery (HRR) indices, all patients underwent an exercise stress test in accordance with the Bruce protocol, reaching at least 85% of the age-predicted heart rates. After achieving peak workload, all patients spent at least 3 min of recovery without cool-down period. HRR indices were calculated by subtracting first, second, and third-minute heart rates from the maximal heart rate obtained during stress testing; these results were designated Rec1, Rec2, and Rec3, respectively.<sup><xref ref-type="bibr" rid="bibr12-0961203311425518">12</xref></sup></p></sec>
<sec id="sec6-0961203311425518"><title>Heart rate variability</title>
<p>Using the ELATEC Holter system, 24-h Holter recordings were obtained by using three-channel analogue recorders. In the heart rate variability (HRV) analysis, the standard parameters obtained from the time-domain analysis of HRV including SDNN (standard deviation of all NN intervals for a selected time period), SDANN (SD of the 5-min mean R–R intervals tabulated over an entire day), RMSSD (square root of the mean of the sum of thesquares of differences between adjacent R–R intervals), and PNN50 (the proportion of differences in successive NN intervals greater than 50 ms) were used. Spectral analysis of HRV is obtained by summing powers of each frequency band; high-frequency (HF) component (0.15–0.40 Hz); low-frequency (LF) component (0.04–0.15 Hz) and very low-frequency component (VLF) (0–0.04 Hz). In all patients the LF power/HF power was calculated.<sup><xref ref-type="bibr" rid="bibr13-0961203311425518">13</xref></sup> In the calculation and analysis of HRV parameters, ELATEC Holter software was used.</p></sec>
<sec id="sec7-0961203311425518"><title>Heart rate turbulence</title>
<p>For heart rate turbulence (HRT) evaluation, two indexes including turbulence onset (TO) and turbulence slope (TS) were calculated as described in previous studies.<sup><xref ref-type="bibr" rid="bibr14-0961203311425518">14</xref></sup> The TO index defines the magnitude of tachycardia after ventricular premature beat by comparing the normal-to-normal interval of the sinus rhythm two beats after the ventricular premature complex (VPC) to normal-to-normal interval of the sinus rhythm 2 beats before the VPC. Thus a TO value ≥0 is accepted as abnormal.<sup><xref ref-type="bibr" rid="bibr15-0961203311425518">15</xref></sup></p></sec>
<sec id="sec8-0961203311425518"><title>QT dispersion</title>
<p>For the evaluation of QT dynamicity, the whole 24-h period was used. A 12-lead ECG was recorded in all patients at a paper speed of 25 mm/s. QT intervals and QT dispersion parameters were measured and calculated using the ELATEC Holter software programme. Recordings were eligible if they had more than 18 h of analysable data. Corrected QT (QTc) was automatically calculated with Bazett’s formula. QTd dispersion was calculated as the difference between maximal and minimal values of QT. The T-wave apex was determined by fitting a parabola through the peak of the T wave, and the end of the T wave was determined by the intersection of the tangent of the downslope of T wave with isoelectric baseline. The software computed the linear regression of QT end/RR slope and QT apex/RR slope and provided the slope and correlation coefficient of these linear regressions.<sup><xref ref-type="bibr" rid="bibr16-0961203311425518">16</xref>,<xref ref-type="bibr" rid="bibr17-0961203311425518">17</xref></sup></p></sec></sec>
<sec id="sec9-0961203311425518"><title>Statistical analysis</title>
<p>Numerical variables with a normal distribution were presented as the mean ± standard deviation (SD), numerical variables with a skewed distribution were presented as the median (minimum and maximum), and categorical variables were presented as percentages. For numerical variables, an independent sample <italic>t</italic>-test and Mann–Whitney <italic>U</italic> test were used for inter-group comparisons. Chi-square test and Fischer’s exact chi-square test were used for comparisons of categorical variables. Correlation was done using Pearson’s correlation coefficient (<italic>r</italic>). Statistical analyses were performed using SPSS statistical software (version 15.0; SPSS Inc., Chicago, Illinois, USA). A two-tailed <italic>p</italic> &lt; 0.05 was considered statistically significant.</p></sec></sec>
<sec id="sec10-0961203311425518" sec-type="results"><title>Results</title>
<p>In this study we enrolled a total of 36 consecutive patients (25 female (69%); mean age 34.2 ± 10.2 years) with SLE and 32 healthy subjects (23 female (71%); mean age 35.0 ± 10.3 years). According to the basic clinical and demographic characteristics, both groups of the study were similar with regard to age, gender, BMI, fasting glucose and serum cholesterol levels. There was no statistically significant difference between patients and control group participants in terms of systolic and diastolic blood pressures, resting heart rate, left ventricular end diastolic dimension or left ventricular ejection fraction. Baseline characteristics of the study population are illustrated in <xref ref-type="table" rid="table1-0961203311425518">Table 1</xref>. In patients with SLE, disease activity index was 5.3 ± 3.9. Lupus manifestations in our cohort included systemic features (100% cases), musculoskeletal (50%), mucocutaneous (80.5%) and haematological (33.3%) features. There were no renal, neurologic and cardiopulmonary features in our study population at the time of study.
<table-wrap id="table1-0961203311425518" position="float"><label>Table 1</label><caption><p>Baseline demographic characteristics and lipid profiles of the SLE and control groups</p></caption>
<graphic alternate-form-of="table1-0961203311425518" xlink:href="10.1177_0961203311425518-table1.tif"/>
<table frame="hsides"><thead align="left">
<tr><th>Parameters</th>
<th>SLE (<italic>n</italic> = 36)</th>
<th>Control group (<italic>n</italic> = 32)</th>
<th><italic>p</italic>-value</th></tr></thead>
<tbody align="left">
<tr>
<td>Age (years)</td>
<td>34.2 ± 10.2</td>
<td>35.0 ± 10.3</td>
<td>NS</td></tr>
<tr>
<td>Gender (F/M)</td>
<td>25/11</td>
<td>23/9</td>
<td>NS</td></tr>
<tr>
<td>BMI (kg/m<sup>2</sup>)</td>
<td>22.6 ± 2.3</td>
<td>22.4 ± 2.2</td>
<td>NS</td></tr>
<tr>
<td>LVEF (%)</td>
<td>64.1 ± 4.3</td>
<td>65.4 ± 3.6</td>
<td>NS</td></tr>
<tr>
<td>LVEDD (mm)</td>
<td>47.0 ± 4.0</td>
<td>48.0 ± 4.0</td>
<td>NS</td></tr>
<tr>
<td>Total cholestrol (mg/dl)</td>
<td>179.0 ± 26.5</td>
<td>176.2 ± 25.8</td>
<td>NS</td></tr>
<tr>
<td>Triglyceride (mg/dl)</td>
<td>119.5 ± 33.0</td>
<td>116.2 ± 31.6</td>
<td>NS</td></tr>
<tr>
<td>HDL-cholestrol (mg/dl)</td>
<td>55.48 ± 12.3</td>
<td>56.5 ± 17.7</td>
<td>NS</td></tr>
<tr>
<td>LDL-cholestrol (mg/dl)</td>
<td>118.5 ± 19.4</td>
<td>109.5 ± 20.6</td>
<td>NS</td></tr>
<tr>
<td>FPG (mg/dl)</td>
<td>82.2 ± 6.5</td>
<td>79.3 ± 4.1</td>
<td>NS</td></tr>
<tr>
<td>Serum creatinine (mg/dl)</td>
<td>0.82 ± 0.15</td>
<td>0.69 ± 0.21</td>
<td>NS</td></tr>
<tr>
<td>Age at diagnosis (years)</td>
<td>32.4 ± 10.8</td>
<td>-</td>
<td>-</td></tr>
<tr>
<td>Disease duration (years)</td>
<td>8.4 ± 4.0</td>
<td>-</td>
<td>-</td></tr>
<tr>
<td>Malar rash</td>
<td>7 (19.4)</td>
<td>-</td>
<td>-</td></tr>
<tr>
<td>Discoid rash</td>
<td>5 (13.9)</td>
<td>-</td>
<td>-</td></tr>
<tr>
<td>Photosensitivity</td>
<td>9 (25%)</td>
<td>-</td>
<td>-</td></tr>
<tr>
<td>Oral ulcers</td>
<td>8 (22.2%)</td>
<td>-</td>
<td>-</td></tr>
<tr>
<td>Arthritis</td>
<td>18 (50%)</td>
<td>-</td>
<td>-</td></tr>
<tr>
<td>Serositis</td>
<td>-</td>
<td>-</td>
<td>-</td></tr>
<tr>
<td>Renal</td>
<td>-</td>
<td>-</td>
<td>-</td></tr>
<tr>
<td>Neurologic</td>
<td>-</td>
<td>-</td>
<td>-</td></tr>
<tr>
<td>Hematologic</td>
<td>12 (33.3%)</td>
<td>-</td>
<td>-</td></tr>
<tr>
<td>SLEDAI score</td>
<td>5.3 ± 3.9</td>
<td>-</td>
<td>-</td></tr>
<tr>
<td>SLICC-DI score</td>
<td>3.1 ± 1.9</td>
<td>-</td>
<td>-</td></tr>
<tr>
<td>Antiphospholipid syndrome</td>
<td>5 (13.9%)</td>
<td>-</td>
<td>-</td></tr>
<tr>
<td>Anti-nuclear antibody</td>
<td>36 (100%)</td>
<td>-</td>
<td>-</td></tr>
<tr>
<td>Anti-dsDNA positive</td>
<td>27 (75%)</td>
<td>-</td>
<td>-</td></tr>
<tr>
<td>Anti-Sm positive</td>
<td>5 (13.9)</td>
<td>-</td>
<td>-</td></tr>
<tr>
<td>Glucocorticoid</td>
<td>21 (58.3%)</td>
<td>-</td>
<td>-</td></tr>
<tr>
<td>Hydroxychloroquine</td>
<td>36 (100%)</td>
<td>-</td>
<td>-</td></tr>
<tr>
<td>Immunosuppressive</td>
<td>15 (41.6%)</td>
<td>-</td>
<td>-</td></tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0961203311425518"><p>Data are given as number (%) or mean ± SD.</p></fn>
<fn id="table-fn2-0961203311425518"><p>anti-dsDNA, anti-double stranded DNA antibodies; anti-Sm, anti-Smith antibodies; BMI, Body mass index; F, female; FPG, fasting plasma glucose; LVEDD, Left ventricle end-diastolic diameter; LVEF, Left ventricle ejection fraction; M, male; SLE, systemic lupus erythematosus; SLEDAI, systemic lupus erythematosus disease activity index; SLICC-DI, Systemic Lupus International Collaborating Clinics Damage Index.</p></fn></table-wrap-foot>
</table-wrap></p>
<p>All patients and control group participants were in sinus rhythm and displayed normal 12-lead ECG results at rest. Study participants completed the exercise stress test without any complications including ischaemic changes or rhythm abnormalities. Exercise test duration (6.9 ± 2.2 vs. 7.2 ± 2.2 min, <italic>p</italic> = 0,826), maximum heart rate (161.5 ± 13.1 vs. 160.2 ± 13.7 bpm, <italic>p</italic> = 0.686) and peak exercise capacity (9.6 ± 2.3 vs. 10.2 ± 2.0 METs, <italic>p</italic> = 0.347) were similar between SLE and control groups. However, mean HRR1 (32.6 ± 10.9 vs. 42.5 ± 6.5, <italic>p</italic> = 0.001), HRR2 (51.0 ± 16.9 vs. 61.0 ± 10.8, <italic>p</italic> = 0.006) and HRR3 (52.8 ± 17.5 vs. 65.8 ± 9.8, <italic>p</italic> &lt; 0.001) values were significantly higher in control group.</p>
<p>The time-domain parameters of HRV were compared between the SLE and control groups; SDNN (61.7 ± 9.5 vs. 83.1 ± 18.0, <italic>p</italic> = 0.001), SDANN (159.6 ± 40.8 vs. 182.1 ± 35.1, <italic>p</italic> = 0.018), RMSSD (44.3 ± 11.7 vs. 70.6 ± 17.9, <italic>p</italic> &lt; 0.001), PNN50 (15.4 ± 3.9 vs. 33.0 ± 9.9, <italic>p</italic> &lt; 0.001) and HF (21.7 ± 7.4 vs. 37.2 ± 13.4 <italic>p</italic> &lt; 0.001) were significantly decreased in patients with SLE compared with healthy controls, as illustrated in <xref ref-type="table" rid="table2-0961203311425518">Table 2</xref>. However LF (66.2 ± 6.0 vs. 54.7 ± 12.6 <italic>p</italic> &lt; 0.001) and LF/HF (3.5 ± 1.6 vs. 1.9 ± 1.1 <italic>p</italic> &lt; 0.001) were significantly higher in SLE patients.
<table-wrap id="table2-0961203311425518" position="float"><label>Table 2</label><caption><p>Comparison of treadmill exercise test, heart rate variability (HRV), QT dispersion and heart rate turbulence (HRT) parameters between patients with SLE and control subjects</p></caption>
<graphic alternate-form-of="table2-0961203311425518" xlink:href="10.1177_0961203311425518-table2.tif"/>
<table frame="hsides"><thead>
<tr><th/>
<th>SLE (<italic>n</italic> = 36)</th>
<th>Control group (<italic>n</italic> = 32)</th>
<th><italic>p</italic>-value</th></tr></thead>
<tbody align="left">
<tr>
<td colspan="4"><bold>Treadmill exercise test parameters</bold></td></tr>
<tr>
<td>Basal heart rate (bpm)</td>
<td>85.6 ± 12.8</td>
<td>84.1 ± 12.9</td>
<td>NS</td></tr>
<tr>
<td>SBP (mmHg)</td>
<td>114.1 ± 13.7</td>
<td>115.1 ± 14.2</td>
<td>NS</td></tr>
<tr>
<td>DBP (mmHg</td>
<td>71.1 ± 8.9</td>
<td>70.1 ± 8.3</td>
<td>NS</td></tr>
<tr>
<td>SPAP (mmHg)</td>
<td>24.4 ± 3.5</td>
<td>22.1 ± 3.8</td>
<td>NS</td></tr>
<tr>
<td>Exercise test duration (min)</td>
<td>6.9 ± 2.2</td>
<td>7.2 ± 2.2</td>
<td>NS</td></tr>
<tr>
<td>Maximum heart rate (bpm)</td>
<td>161.5 ± 13.1</td>
<td>160.2 ± 13.7</td>
<td>NS</td></tr>
<tr>
<td>Peak exercise capacity (METS)</td>
<td>9.6 ± 2.3</td>
<td>10.2 ± 2.0</td>
<td>NS</td></tr>
<tr>
<td>HRR1</td>
<td>32.6 ± 10.9</td>
<td>42.5 ± 6.5</td>
<td>0.001</td></tr>
<tr>
<td>HRR2</td>
<td>51.0 ± 16.9</td>
<td>61.0 ± 10.8</td>
<td>0.006</td></tr>
<tr>
<td>HRR3</td>
<td>52.8 ± 17.5</td>
<td>65.8 ± 9.8</td>
<td>&lt;0.001</td></tr>
<tr>
<td colspan="4"><bold>HRV parameters</bold></td></tr>
<tr>
<td>Mean RR</td>
<td>783 ± 81</td>
<td>764 ± 96</td>
<td>NS</td></tr>
<tr>
<td>Mean heart rate (bpm)</td>
<td>72.4±9.0</td>
<td>70.4 ± 8.2</td>
<td>NS</td></tr>
<tr>
<td>SDNN (ms)</td>
<td>61.7 ± 9.5</td>
<td>83.1 ± 18.0</td>
<td>0.001</td></tr>
<tr>
<td>SDANN (ms)</td>
<td>159.6 ± 40.8</td>
<td>182.1 ± 35.1</td>
<td>0.018</td></tr>
<tr>
<td>RMSDD (ms)</td>
<td>44.3 ± 11.7</td>
<td>70.6 ± 17.9</td>
<td>&lt;0.001</td></tr>
<tr>
<td>VarIndex (%)</td>
<td>2.9 ± 0.4</td>
<td>4.5 ± 1.5</td>
<td>&lt;0.001</td></tr>
<tr>
<td>PNN50 (%)</td>
<td>15.4 ± 3.9</td>
<td>33.0 ± 9.9</td>
<td>&lt;0.001</td></tr>
<tr>
<td>LF n.u. (%)</td>
<td>66.2 ± 6.0</td>
<td>54.7 ± 12.6</td>
<td>&lt;0.001</td></tr>
<tr>
<td>HF n.u. (%)</td>
<td>21.7 ± 7.4</td>
<td>37.2 ± 13.4</td>
<td>&lt;0.001</td></tr>
<tr>
<td>LF/HF</td>
<td>3.5 ± 1.6</td>
<td>1.9 ± 1.1</td>
<td>&lt;0.001</td></tr>
<tr>
<td colspan="4"><bold>QT intervals and dispersion</bold></td></tr>
<tr>
<td>Mean QTac</td>
<td>376.0 ± 15.7</td>
<td>338.3 ± 15.3</td>
<td>0.0064</td></tr>
<tr>
<td>Mean QTec</td>
<td>439.9 ± 20.0</td>
<td>416.9 ± 16.9</td>
<td>0.0025</td></tr>
<tr>
<td>QTd</td>
<td>81.3 ± 15.8</td>
<td>53.2 ± 13.1</td>
<td>&lt;0.001</td></tr>
<tr>
<td>QTcd</td>
<td>80.7 ± 14.6</td>
<td>51.1 ± 12.7</td>
<td>&lt;0.001</td></tr>
<tr>
<td>QTac/RR slope</td>
<td>0.21 ± 0.06</td>
<td>0.15 ± 0.04</td>
<td>&lt;0.001</td></tr>
<tr>
<td>QTec/RR slope</td>
<td>0.20 ± 0.04</td>
<td>0.13 ± 0.04</td>
<td>&lt;0.001</td></tr>
<tr>
<td colspan="4"><bold>HRT parameters</bold></td></tr>
<tr>
<td>HRT onset (%)</td>
<td>−0.010 ± 0.045</td>
<td>−0.178 ± 0.158</td>
<td>0.025</td></tr>
<tr>
<td>HRT slope (ms/beat)</td>
<td>5.1 ± 2.6</td>
<td>9.4 ± 3.4</td>
<td>0.034</td></tr>
<tr>
<td>Abnormal HRT onset</td>
<td>9/36 (25%)</td>
<td>3/32 (9.3%)</td>
<td>&lt;0.001</td></tr>
<tr>
<td>Abnormal HRT slope</td>
<td>7/36 (19.4%)</td>
<td>3/32 (9.3%)</td>
<td>&lt;0.001</td></tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn3-0961203311425518"><p>Numerical variables with a normal distribution were presented as the mean ± standard deviation.</p></fn>
<fn id="table-fn4-0961203311425518"><p>DBP, Diastolic blood pressure before exercise; HF, high-frequency component; HRR, heart rate recovery; LF, low-frequency component; NS, nonsignificant; pNN50, the number of pairs of adjacent NN intervals differing by more than 50 ms divided by the total number of all NN intervals; RMSSD, the square root of the mean of the sum of the squares of differences between adjacent NN intervals; SBP, systolic blood pressure before exercise; SDNN, standard deviations of all NN intervals; SDANN, standard deviation of the averages of NN intervals in all 5-min segments of the entire recording.</p></fn></table-wrap-foot>
</table-wrap></p>
<p>When QT dispersion parameters considered, the QT dispersion value was significantly higher in SLE patients than in control subjects (<xref ref-type="fig" rid="fig1-0961203311425518">Figure 1</xref>); mean QTac (376.0 ± 15.7 vs. 338.3 ± 15.3, <italic>p</italic> = 0.006), mean QTec (439.9 ± 20.0 vs. 416.9 ± 16.9, <italic>p</italic> = 0.002), QTd (81.3 ± 15.8 vs. 53.2 ± 13.1, <italic>p</italic> &lt; 0.001), QTcd (80.7 ± 14.6 vs. 51.1 ± 12.7, <italic>p</italic> &lt; 0.001), QTac/RR slope (0.21 ± 0.06 vs. 0.15 ± 0.04, <italic>p</italic> &lt; 0.001) and QTec/RR slope (0.20 ± 0.04 vs. 0.13 ± 0.04, <italic>p</italic> &lt; 0.001).
<fig id="fig1-0961203311425518" position="float"><label>Figure 1</label><caption><p>Comparison of the QT dynamicity parameters between patients with SLE and the control group.</p></caption><graphic xlink:href="10.1177_0961203311425518-fig1.tif"/></fig></p>
<p>When HRT parameters were compared, the values of the HRT onset and HRT slope were significantly less negative in SLE patients than the control group (−0.010 ± 0.045 vs. −0.178 ± 0.158 %, <italic>p</italic> = 0.025 and 5.1 ± 2.6 vs. 9.4 ± 3.4, <italic>p</italic> = 0.034 respectively). Abnormal HRT onset and HRT slope parameters were significantly higher in the SLE group, as illustrated in <xref ref-type="table" rid="table2-0961203311425518">Table 2</xref> (<italic>p</italic> &lt; 0.001).</p>
<p>There were no correlations between the disease duration and SDANN (<italic>r</italic> = 0.03, <italic>p</italic> = 0.35), LF power (<italic>r</italic> = 0.25, <italic>p</italic> = 0.44), LF/HF ratio (<italic>r</italic> = 0.31, <italic>p</italic> = 0.06), TO (<italic>r</italic> = 0.23, <italic>p</italic> = 0.54), TS (<italic>r</italic> = 0.05, <italic>p</italic> = 0.76), HRR1 (<italic>r</italic> = 0.11, <italic>p</italic> = 0.52), HRR2 (<italic>r</italic> = 0.16, <italic>p</italic> = 0.42) and HRR3 (<italic>r</italic> = 0.08, <italic>p</italic> = 0.35). Also, there was no correlation between SLEDAI/SLICC-DI scores and SDANN (<italic>r</italic> = 0.08, <italic>p</italic> = 0.34; <italic>r</italic> = 0.15, <italic>p</italic> = 0.14), LF power (<italic>r</italic> = 0.23, <italic>p</italic> = 0.13; <italic>r</italic> = 0.25, <italic>p</italic> = 0.54), LF/HF ratio (<italic>r</italic> = 0.36, <italic>p</italic> = 0.07; <italic>r</italic> = 0.35, <italic>p</italic> = 0.06), TO (<italic>r</italic> = 0.33, <italic>p</italic> = 0.054; <italic>r</italic> = 0.125, <italic>p</italic> = 0.064), TS (<italic>r</italic> = 0.125, <italic>p</italic> = 0.176; <italic>r</italic> = 0.32, <italic>p</italic> = 0.054), HRR1 (<italic>r</italic> = 0.16, <italic>p</italic> = 0.57; <italic>r</italic> = 0.12, <italic>p</italic> = 0.44), HRR2 (<italic>r</italic> = 0.016, <italic>p</italic> = 0.45; <italic>r</italic> = 0.026, <italic>p</italic> = 0.74) and HRR3 (<italic>r</italic> = 0.07, <italic>p</italic> = 0.235; <italic>r</italic> = 0.125, <italic>p</italic> = 0.24). No particular organ involvement predicted the presence or absence of cardiac dysautonomia.</p></sec>
<sec id="sec11-0961203311425518" sec-type="discussion"><title>Discussion</title>
<p>Our study results indicate that several indices of autonomic functions were impaired in patients with SLE. Unlike previous reports investigating autonomic functions in SLE patients, in our study HRR, HRV, QT dispersion and HRT were impaired in SLE patients when compared with healthy subjects. To the best of our knowledge this is the first study in the literature evaluating several indices of autonomic functions assessed by both exercise stress test and ambulatory Holter recording in SLE patients. These results may explain the increased occurrence of arrhythmias and sudden cardiac death in SLE patients. Since the determination of HRR, HRV, HRT and QT dispersion as indices of autonomic functions is non-invasive, those methods can be easily used in patients with SLE.</p>
<p>Cardiovascular diseases are the leading causes ofmorbidity and mortality among patients with autoimmune diseases.<sup><xref ref-type="bibr" rid="bibr18-0961203311425518">18</xref></sup> In addition to accelerated atherosclerosis, conduction disturbances and rhythm disorders are important manifestations of cardiac involvement in autoimmune rheumatic diseases including SLE.<sup><xref ref-type="bibr" rid="bibr19-0961203311425518">19</xref></sup> However, cardiac autonomic dysfunction may also disturb indices of autonomic functions without overt cardiac involvement. Sinus tachycardia, atrial fibrillation and atrial ectopic beats are the most common presentation of rhythm disorders in SLE.<sup><xref ref-type="bibr" rid="bibr20-0961203311425518">20</xref></sup> In addition, sinus bradycardia and QT prolongation have also been described in SLE patients, as well as malignant ventricular arrhythmias.<sup><xref ref-type="bibr" rid="bibr21-0961203311425518">21</xref></sup> Despite the rare reports of sudden cardiac death in SLE, abnormalities in the autonomic tone and ventricular repolarization may potentially induce malignant ventricular arrhythmias.<sup><xref ref-type="bibr" rid="bibr4-0961203311425518">4</xref></sup></p>
<p>Several previous studies investigated the association between autoimmune diseases, including SLE, and several indices of cardiac autonomic dysfunction.<sup><xref ref-type="bibr" rid="bibr6-0961203311425518">6</xref>,<xref ref-type="bibr" rid="bibr7-0961203311425518">7</xref>,<xref ref-type="bibr" rid="bibr22-0961203311425518">22</xref></sup> The ANS plays a pivotal role in the regulation of cardiovascular functions. During exercise, a simultaneous increase in the sympathetic nervous system activity and the suppression of parasympathetic nervous system activity causes an increase in heart rate as a physiological response. On the other hand, parasympathetic activation together with sympathetic withdrawal causes a fall in heart rate immediately after exercise.<sup><xref ref-type="bibr" rid="bibr12-0961203311425518">12</xref></sup> An abnormal HRR, which was defined as a failure of heart rate to decrease 12 beats or more during the first minute after peak exercise, is an independent predictor of adverse cardiovascular outcomes.<sup><xref ref-type="bibr" rid="bibr23-0961203311425518">23</xref>,<xref ref-type="bibr" rid="bibr24-0961203311425518">24</xref></sup> In addition, Jouven and colleagues<sup><xref ref-type="bibr" rid="bibr25-0961203311425518">25</xref></sup> demonstrated that a HRR less than 25 beats/min at 1 min of the recovery period carried 2.1 times the risk of sudden death, 0.9 times the risk of non-sudden death, and 1.3 times the risk of death from any cause. In a recent study by Dogdu et al.<sup><xref ref-type="bibr" rid="bibr26-0961203311425518">26</xref></sup> the HRR index was evaluated in patients with SLE; these authors found significant differences in HRR(1) and HRR(2) indices between SLE patients and the control group. As in line with this study, we found significant differences in HRR(1), HRR(2) and HRR(3) between SLE patients and the control group, defining deterioration in HRR index among patients with SLE.</p>
<p>QT dispersion is defined as the variability of the duration of the QT interval in electrocardiography, which can indicate the homogeneity of cardiac repolarization.<sup><xref ref-type="bibr" rid="bibr16-0961203311425518">16</xref></sup> In addition to myocardial involvement, autonomic dysfunction may also cause impaired repolarization mechanisms, leading to increased QT dispersion in autoimmune diseases. In a previous study by Yavuz et al.<sup><xref ref-type="bibr" rid="bibr27-0961203311425518">27</xref></sup> QT dispersion was significantly increased in SLE patients without overt cardiac involvement. In the present study, wefound that QT dispersion was significantly higher in patients with SLE than in healthy control subjects.</p>
<p>HRT is an emerging method in the evaluation ofcardiac autonomic functions which denotes thebaroreflex-mediated oscillation of cardiac cycle lengths after spontaneous ventricular premature complexes. Previous reports showed that HRT was an independent and powerful predictor of mortality after myocardial infarction, with greater predictive power than HRV.<sup><xref ref-type="bibr" rid="bibr28-0961203311425518">28</xref></sup> In a recent study by Bienias et al.<sup><xref ref-type="bibr" rid="bibr29-0961203311425518">29</xref></sup> HRT was assessed in patients with systemic sclerosis, revealing significant HRT impairment in systemic sclerosis compared with healthy subjects. To our knowledge, there has been no study in the literature evaluating the HRT in patients with SLE. In our study, HRT was significantly impaired in SLE patients compared with healthy controls.</p>
<p>In the present study, we also analysed HRV in our study group. Cardiac autonomic profile was evaluated in SLE patients In a study by Stein et al.,<sup><xref ref-type="bibr" rid="bibr30-0961203311425518">30</xref></sup> which demonstrated that time and frequency domain HRV indices were significantly reduced in the SLE groups as compared with controls. In addition, Laganá et al.<sup><xref ref-type="bibr" rid="bibr31-0961203311425518">31</xref></sup> found that HRV indices were impaired in patients with SLE. As in line with previous studies, in our study, time-domain parameters of HRV including SDNN, SDANN, RMSSD, PNN50 and HF were significantly decreased in patients with SLE compared with healthy controls, whereas LF and LF/HF were higher in SLE patients.</p>
<p>The main strength of our study is the demonstration of cardiac autonomic dysfunction with several indices in SLE patients. However, our study has some limitations. First, our study group consisted of a relatively small number of patients from a single centre. Second, this is a cross-sectional study aimed at evaluating cardiac autonomic dysfunctions in SLE patients. Third, despite the similarities in echocardiographic findings between SLE patients and the control group, more sensitive methods evaluating myocardial involvement, such as SPECT or cardiac MRI, may be used. Further prospective studies are needed to elucidate the exact pathophysiological mechanisms underlying autoimmune disorders and clinical implications of impaired autonomic functions in these patients.</p>
<p>In conclusion, SLE is associated with impaired cardiac autonomic functions. As autoimmune diseases including SLE are characterized by a high degree of cardiovascular risk, and cardiac involvement is associated with adverse outcomes and a poor prognosis, the early identification of patients at higher risk is essential. Despite the paucity of data regarding the pathogenesis and clinical implications of autonomic dysfunction in SLE, close clinical follow-up is crucial in patients with SLE, which may be useful in order to identify high-risk patients. Large-scale, prospective, randomized and controlled studies would be useful to detect the prognostic significance of HRR, HRV, HRT parameters and QT dynamicity in patients with SLE.</p></sec>
</body>
<back>
<sec id="sec12-0961203311425518"><title>Funding</title>
<p>This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.</p></sec>
<sec id="sec13-0961203311425518"><title>Conflict of interest</title>
<p>The authors do not have any conflict of interest.</p></sec>
<ref-list>
<title>References</title>
<ref id="bibr1-0961203311425518"><label>1.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sofat</surname><given-names>N</given-names></name><name><surname>Malik</surname><given-names>O</given-names></name><name><surname>Higgens</surname><given-names>CS</given-names></name></person-group>. <article-title>Neurological involvement in patients with rheumatic disease</article-title>. <source>QJM</source> <year>2006</year>; <volume>99</volume>: <fpage>69</fpage>–<lpage>79</lpage>.</citation></ref>
<ref id="bibr2-0961203311425518"><label>2.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bjornadal</surname><given-names>L</given-names></name><name><surname>Yin</surname><given-names>L</given-names></name><name><surname>Granath</surname><given-names>F</given-names></name><name><surname>Klareskog</surname><given-names>L</given-names></name><name><surname>Ekbom</surname><given-names>A</given-names></name></person-group>. <article-title>Cardiovascular disease a hazard despite improved prognosis in patients with systemic lupus erythematosus: results from a Swedish population based study 1964-95</article-title>. <source>J Rheumatol</source> <year>2004</year>; <volume>31</volume>: <fpage>713</fpage>–<lpage>719</lpage>.</citation></ref>
<ref id="bibr3-0961203311425518"><label>3.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Karadag</surname><given-names>O</given-names></name><name><surname>Calguneri</surname><given-names>M</given-names></name><name><surname>Atalar</surname><given-names>E</given-names></name><etal/></person-group>. <article-title>Novel cardiovascular risk factors and cardiac event predictors in female inactive systemic lupus erythematosus patients</article-title>. <source>Clin Rheumatol</source> <year>2007</year>; <volume>26</volume>: <fpage>695</fpage>–<lpage>699</lpage>.</citation></ref>
<ref id="bibr4-0961203311425518"><label>4.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lazzerini</surname><given-names>PE</given-names></name><name><surname>Capecchi</surname><given-names>PL</given-names></name><name><surname>Guideri</surname><given-names>F</given-names></name><name><surname>Acampa</surname><given-names>M</given-names></name><name><surname>Galeazzi</surname><given-names>M</given-names></name><name><surname>Laghi Pasini</surname><given-names>F</given-names></name></person-group>. <article-title>Connective tissue diseases and cardiac rhythm disorders: an overview</article-title>. <source>Autoimmun Rev</source> <year>2006</year>; <volume>5</volume>: <fpage>306</fpage>–<lpage>313</lpage>.</citation></ref>
<ref id="bibr5-0961203311425518"><label>5.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lazzerini</surname><given-names>PE</given-names></name><name><surname>Capecchi</surname><given-names>PL</given-names></name><name><surname>Guideri</surname><given-names>F</given-names></name><etal/></person-group>. <article-title>Comparison of frequency of complex ventricular arrhythmias in patients with positive versus negative anti-Ro/SSA and connective tissue disease</article-title>. <source>Am J Cardiol</source> <year>2007</year>; <volume>100</volume>: <fpage>1029</fpage>–<lpage>1034</lpage>.</citation></ref>
<ref id="bibr6-0961203311425518"><label>6.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Aydemir</surname><given-names>M</given-names></name><name><surname>Yazisiz</surname><given-names>V</given-names></name><name><surname>Basarici</surname><given-names>I</given-names></name><etal/></person-group>. <article-title>Cardiac autonomic profile in rheumatoid arthritis and systemic lupus erythematosus</article-title>. <source>Lupus</source> <year>2010</year>; <volume>19</volume>: <fpage>255</fpage>–<lpage>261</lpage>.</citation></ref>
<ref id="bibr7-0961203311425518"><label>7.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kaya</surname><given-names>EB</given-names></name><name><surname>Yorgun</surname><given-names>H</given-names></name><name><surname>Akdogan</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Heart-rate recovery index is impaired in Behcet's disease</article-title>. <source>Tex Heart Inst J</source> <year>2009</year>; <volume>36</volume>: <fpage>282</fpage>–<lpage>286</lpage>.</citation></ref>
<ref id="bibr8-0961203311425518"><label>8.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tan</surname><given-names>EM</given-names></name><name><surname>Cohen</surname><given-names>AS</given-names></name><name><surname>Fries</surname><given-names>JF</given-names></name><etal/></person-group>. <article-title>The 1982 revised criteria for the classification of systemic lupus erythematosus</article-title>. <source>Arthritis Rheum</source> <year>1982</year>; <volume>25</volume>: <fpage>1271</fpage>–<lpage>1277</lpage>.</citation></ref>
<ref id="bibr9-0961203311425518"><label>9.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bombardier</surname><given-names>C</given-names></name><name><surname>Gladman</surname><given-names>DD</given-names></name><name><surname>Urowitz</surname><given-names>MB</given-names></name><name><surname>Caron</surname><given-names>D</given-names></name><name><surname>Chang</surname><given-names>CH</given-names></name></person-group>. <article-title>Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE</article-title>. <source>Arthritis Rheum</source> <year>1992</year>; <volume>35</volume>: <fpage>630</fpage>–<lpage>640</lpage>.</citation></ref>
<ref id="bibr10-0961203311425518"><label>10.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gladman</surname><given-names>D</given-names></name><name><surname>Ginzler</surname><given-names>E</given-names></name><name><surname>Goldsmith</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>The development andinitial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus</article-title>. <source>Arthritis Rheum</source> <year>1996</year>; <volume>39</volume>: <fpage>363</fpage>–<lpage>369</lpage>.</citation></ref>
<ref id="bibr11-0961203311425518"><label>11.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gladman</surname><given-names>DD</given-names></name><name><surname>Ibanez</surname><given-names>D</given-names></name><name><surname>Urowitz</surname><given-names>MB</given-names></name></person-group>. <article-title>Systemic Lupus Erythematosus Disease Activity Index 2000</article-title>. <source>J Rheumatol</source> <year>2002</year>; <volume>29</volume>: <fpage>288</fpage>–<lpage>291</lpage>.</citation></ref>
<ref id="bibr12-0961203311425518"><label>12.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cole</surname><given-names>CR</given-names></name><name><surname>Blackstone</surname><given-names>EH</given-names></name><name><surname>Pashkow</surname><given-names>FJ</given-names></name><name><surname>Snader</surname><given-names>CE</given-names></name><name><surname>Lauer</surname><given-names>MS</given-names></name></person-group>. <article-title>Heart-rate recovery immediately after exercise as a predictor of mortality</article-title>. <source>N Engl J Med</source> <year>1999</year>; <volume>341</volume>: <fpage>1351</fpage>–<lpage>1357</lpage>.</citation></ref>
<ref id="bibr13-0961203311425518"><label>13.</label><citation citation-type="journal"><collab>Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology</collab>. <article-title>Heart rate variability: standards of measurement, physiological interpretation and clinical use</article-title>. <source>Circulation</source> <year>1996</year>; <volume>93</volume>: <fpage>1043</fpage>–<lpage>1065</lpage>.</citation></ref>
<ref id="bibr14-0961203311425518"><label>14.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stein</surname><given-names>PK</given-names></name><name><surname>Deedwania</surname><given-names>P</given-names></name></person-group>. <article-title>Usefulness of abnormal heart rate turbulence to predict cardiovascular mortality in high-risk patients with acute myocardial infarction and left ventricular dysfunction (from the EPHESUS study)</article-title>. <source>Am J Cardiol</source> <year>2009</year>; <volume>103</volume>: <fpage>1495</fpage>–<lpage>1499</lpage>.</citation></ref>
<ref id="bibr15-0961203311425518"><label>15.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bauer</surname><given-names>A</given-names></name><name><surname>Malik</surname><given-names>M</given-names></name><name><surname>Schmidt</surname><given-names>G</given-names></name><etal/></person-group>. <article-title>Heart rate turbulence: standards of measurement, physiological interpretation, and clinical use: International Society for Holter and Noninvasive Electrophysiology Consensus</article-title>. <source>J Am Coll Cardiol</source> <year>2008</year>; <volume>52</volume>: <fpage>1353</fpage>–<lpage>1365</lpage>.</citation></ref>
<ref id="bibr16-0961203311425518"><label>16.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kautzner</surname><given-names>J</given-names></name><name><surname>Malik</surname><given-names>M</given-names></name></person-group>. <article-title>QT interval dispersion and its clinical utility</article-title>. <source>Pacing Clin Electrophysiol</source> <year>1997</year>; <volume>20</volume>: <fpage>2625</fpage>–<lpage>2640</lpage>.</citation></ref>
<ref id="bibr17-0961203311425518"><label>17.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zabel</surname><given-names>M</given-names></name><name><surname>Portnoy</surname><given-names>S</given-names></name><name><surname>Franz</surname><given-names>MR</given-names></name></person-group>. <article-title>Electrocardiographic indexes of dispersion of ventricular repolarization: an isolated heart validation study</article-title>. <source>J Am Coll Cardiol</source> <year>1995</year>; <volume>25</volume>: <fpage>746</fpage>–<lpage>752</lpage>.</citation></ref>
<ref id="bibr18-0961203311425518"><label>18.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Knockaert</surname><given-names>DC</given-names></name></person-group>. <article-title>Cardiac involvement in systemic inflammatory diseases</article-title>. <source>Eur Heart J</source> <year>2007</year>; <volume>28</volume>: <fpage>1797</fpage>–<lpage>1804</lpage>.</citation></ref>
<ref id="bibr19-0961203311425518"><label>19.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Abu-Shakra</surname><given-names>M</given-names></name><name><surname>Urowitz</surname><given-names>MB</given-names></name><name><surname>Gladman</surname><given-names>DD</given-names></name><name><surname>Gough</surname><given-names>J</given-names></name></person-group>. <article-title>Mortality studies in systemic lupus erythematosus. Results from a single center. I. Causes of death</article-title>. <source>J Rheumatol</source> <year>1995</year>; <volume>22</volume>: <fpage>1259</fpage>–<lpage>1264</lpage>.</citation></ref>
<ref id="bibr20-0961203311425518"><label>20.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Seferovic</surname><given-names>PM</given-names></name><name><surname>Ristic</surname><given-names>AD</given-names></name><name><surname>Maksimovic</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>Cardiac arrhythmias and conduction disturbances in autoimmune rheumatic diseases</article-title>. <source>Rheumatology (Oxford)</source> <year>2006</year>; <volume>45</volume>(<issue>Suppl 4</issue>): <fpage>iv39</fpage>–<lpage>iv42</lpage>.</citation></ref>
<ref id="bibr21-0961203311425518"><label>21.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lazzerini</surname><given-names>PE</given-names></name><name><surname>Acampa</surname><given-names>M</given-names></name><name><surname>Guideri</surname><given-names>F</given-names></name><etal/></person-group>. <article-title>Prolongation of the corrected QT interval in adult patients with anti-Ro/SSA-positive connective tissue diseases</article-title>. <source>Arthritis Rheum</source> <year>2004</year>; <volume>50</volume>: <fpage>1248</fpage>–<lpage>1252</lpage>.</citation></ref>
<ref id="bibr22-0961203311425518"><label>22.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ardic</surname><given-names>I</given-names></name><name><surname>Kaya</surname><given-names>MG</given-names></name><name><surname>Yarlioglues</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Assessment of heart rate recovery index in patients with familial Mediterranean fever</article-title>. <source>Rheumatol Int</source> <year>2011</year>; <volume>31</volume>: <fpage>121</fpage>–<lpage>125</lpage>.</citation></ref>
<ref id="bibr23-0961203311425518"><label>23.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Morshedi-Meibodi</surname><given-names>A</given-names></name><name><surname>Larson</surname><given-names>MG</given-names></name><name><surname>Levy</surname><given-names>D</given-names></name><name><surname>O'Donnell</surname><given-names>CJ</given-names></name><name><surname>Vasan</surname><given-names>RS</given-names></name></person-group>. <article-title>Heart rate recovery after treadmill exercise testing and risk of cardiovascular disease events (The Framingham Heart Study)</article-title>. <source>Am J Cardiol</source> <year>2002</year>; <volume>90</volume>: <fpage>848</fpage>–<lpage>852</lpage>.</citation></ref>
<ref id="bibr24-0961203311425518"><label>24.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mora</surname><given-names>S</given-names></name><name><surname>Redberg</surname><given-names>RF</given-names></name><name><surname>Cui</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>Ability of exercise testing to predict cardiovascular and all-cause death in asymptomatic women: a 20-year follow-up of the lipid research clinics prevalence study</article-title>. <source>JAMA</source> <year>2003</year>; <volume>290</volume>: <fpage>1600</fpage>–<lpage>1607</lpage>.</citation></ref>
<ref id="bibr25-0961203311425518"><label>25.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jouven</surname><given-names>X</given-names></name><name><surname>Empana</surname><given-names>JP</given-names></name><name><surname>Schwartz</surname><given-names>PJ</given-names></name><name><surname>Desnos</surname><given-names>M</given-names></name><name><surname>Courbon</surname><given-names>D</given-names></name><name><surname>Ducimetiere</surname><given-names>P</given-names></name></person-group>. <article-title>Heart-rate profile during exercise as a predictor of sudden death</article-title>. <source>N Engl J Med</source> <year>2005</year>; <volume>352</volume>: <fpage>1951</fpage>–<lpage>1958</lpage>.</citation></ref>
<ref id="bibr26-0961203311425518"><label>26.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dogdu</surname><given-names>O</given-names></name><name><surname>Yarlioglues</surname><given-names>M</given-names></name><name><surname>Kaya</surname><given-names>MG</given-names></name><etal/></person-group>. <article-title>Deterioration of heart rate recovery index in patients with systemic lupus erythematosus</article-title>. <source>J Rheumatol</source> <year>2010</year>; <volume>37</volume>: <fpage>2511</fpage>–<lpage>2515</lpage>.</citation></ref>
<ref id="bibr27-0961203311425518"><label>27.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yavuz</surname><given-names>B</given-names></name><name><surname>Atalar</surname><given-names>E</given-names></name><name><surname>Karadag</surname><given-names>O</given-names></name><etal/></person-group>. <article-title>QT dispersion increases in patients with systemic lupus erythematosus</article-title>. <source>Clin Rheumatol</source> <year>2007</year>; <volume>26</volume>: <fpage>376</fpage>–<lpage>379</lpage>.</citation></ref>
<ref id="bibr28-0961203311425518"><label>28.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schmidt</surname><given-names>G</given-names></name><name><surname>Malik</surname><given-names>M</given-names></name><name><surname>Barthel</surname><given-names>P</given-names></name><etal/></person-group>. <article-title>Heart-rate turbulence after ventricular premature beats as a predictor of mortality after acute myocardial infarction</article-title>. <source>Lancet</source> <year>1999</year>; <volume>353</volume>: <fpage>1390</fpage>–<lpage>1396</lpage>.</citation></ref>
<ref id="bibr29-0961203311425518"><label>29.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bienias</surname><given-names>P</given-names></name><name><surname>Ciurzynski</surname><given-names>M</given-names></name><name><surname>Glinska-Wielochowska</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Heart rateturbulence impairment and ventricular arrhythmias in patients with systemic sclerosis</article-title>. <source>Pacing Clin Electrophysiol</source> <year>2010</year>; <volume>33</volume>: <fpage>920</fpage>–<lpage>928</lpage>.</citation></ref>
<ref id="bibr30-0961203311425518"><label>30.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stein</surname><given-names>KS</given-names></name><name><surname>McFarlane</surname><given-names>IC</given-names></name><name><surname>Goldberg</surname><given-names>N</given-names></name><name><surname>Ginzler</surname><given-names>EM</given-names></name></person-group>. <article-title>Heart rate variability in patients with systemic lupus erythematosus</article-title>. <source>Lupus</source> <year>1996</year>; <volume>5</volume>: <fpage>44</fpage>–<lpage>48</lpage>.</citation></ref>
<ref id="bibr31-0961203311425518"><label>31.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lagana</surname><given-names>B</given-names></name><name><surname>Tubani</surname><given-names>L</given-names></name><name><surname>Maffeo</surname><given-names>N</given-names></name><etal/></person-group>. <article-title>Heart rate variability and cardiac autonomic function in systemic lupus erythematosus</article-title>. <source>Lupus</source> <year>1996</year>; <volume>5</volume>: <fpage>49</fpage>–<lpage>55</lpage>.</citation></ref>
</ref-list>
</back>
</article>